ABSTRACT SARS-CoV-2 B. 1.1. 529.1 (Omicron BA. 1) emerged in November 2021 and
quickly became the predominant circulating SARS-CoV-2 variant globally. Omicron BA. 1 …

The omicron variants of SARS-CoV-2 have substantial ability to escape infection-and
vaccine-elicited antibody immunity. Here, we investigated the extent of such escape in nine …

SARS-CoV-2 Omicron subvariants have generated a worldwide health crisis due to
resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of …

The extent to which Omicron infection,,,,,,,–, with or without previous vaccination, elicits
protection against the previously dominant Delta (B. 1.617. 2) variant is unclear. Here we …

New genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
constantly emerge through unmitigated spread of the virus in the ongoing Coronavirus …

The recently emerged Omicron (B. 1.1. 529) variant has rapidly surpassed Delta to become
the predominant circulating SARS-CoV-2 variant, given the higher transmissibility rate and …

COVID-19 has emerged as a pandemic leading to a global public health crisis of
unprecedented morbidity. A comprehensive insight into the imaging of COVID-19 has …

Background Convalescent plasma has been proposed as an early treatment to interrupt the
progression of early COVID-19 to severe disease, but there is little definitive evidence. We …

The large number of spike substitutions in Omicron lineage variants (BA. 1, BA. 1.1., and BA.
2) could jeopardize the efficacy of SARS-CoV-2 vaccines. We evaluated in mice the …

In parallel with vaccination, oral antiviral agents are highly anticipated to act as
countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic …